Verzenio Improves Overall Survival in Hormone Receptor-Positive, HER2-Negative, Advanced Stage Breast Cancer

episode

Breastcancer.org Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-20-2026 8PM EDT 5 min · 21 Sep 2026 · NPR News Now

Send Me To Sleep | Descartes 38 min · 21 Sep 2026 · Send Me To Sleep

8PM ET 09/20/2026 Newscast 3 min · 21 Sep 2026 · Fox News Hourly Update

Send Me To Sleep | Descartes (Voice Only) 36 min · 21 Sep 2026 · Send Me To Sleep

Nikita Hand: ‘Not the Perfect Victim’ and life after Conor McGregor 26 min · 21 Sep 2026 · The Indo Daily

Simmo Says - What can we name this instant classic | The Means Test with Adam Simpson! (21.09.26) 2 min · 21 Sep 2026 · Whateley

Report any issue

Source

Recorded28 Sep 2022

Publisherfeeds.megaphone.fm ↗

Handlerec:11088158

Show notes

At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer. Listen to the podcast to hear Dr. Goetz explain: how Verzenio works the aims of MONARCH 3 study the difference between progression-free and overall survival and why each is important Verzenio side effects what the results mean for people diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in